Verve Therapeutics Secures $58.5 Million Series A Financing to Advance Gene-Editing Therapies for Coronary Artery Disease

VCBeat (WeChat Official Account: vcbeat) learned from foreign media that on May 7, U.S. local time, medical technology company Verve Therapeutics completed a $58.5 million Series A financing round. The funds from this round will be used to support the company in advancing its next phase of gene-editing therapy research, helping patients prevent and treat coronary artery disease.

It is reported that this round of financing was led by GV, with participation from ARCH Venture Partners, F-Prime Capital Partners, and Biomatics Capital Partners.

Verve Therapeutics, founded in 2018 and headquartered in Massachusetts, USA, is a medical technology company. The company is dedicated to developing gene-editing technologies to help adults optimize their genomic structure, thereby preventing and treating coronary artery disease.

Gene mutation is a type of genetic variation characterized by changes in gene sequence and alterations in gene structure. Gene mutations can occur spontaneously in the human body at any time. While most mutations are harmless, some mutant genes may encode dysfunctional proteins, thereby causing diseases.

Coronary artery disease is the most common form of heart disease and carries a high mortality rate. According to genetic research conducted by Verve Therapeutics, naturally occurring genetic variants can significantly reduce the risk of coronary artery disease in certain individuals. Leveraging these findings, the company has developed CRISPR-Cas genome-editing nucleases designed to prevent coronary artery disease by mimicking natural mutations through targeted intervention. These CRISPR-Cas genome-editing nucleases emulate the mechanisms of natural genetic mutations, precisely targeting specific genomic loci to induce spontaneous changes in the target DNA structure. This process facilitates the production of proteins and other beneficial molecules that help prevent coronary artery disease, thereby maintaining overall health.

Compared with the mainstream therapeutic drugs currently available in the medical market, this gene mutation-guided therapy offers greater advantages. Traditional medications not only require long-term administration but also cause side effects that can damage healthy human tissues to some extent. By directly modifying genetic structures, patients can be relieved from suffering, while treatment efficiency is improved and medical costs are reduced.

GV, founded in 2008 and headquartered in California, USA, is a venture capital firm that focuses on investing in the early and late stages of technology startups. It has completed 641 investments to date. GV provides companies with financial support and professional management teams, leveraging its extensive market resources to help businesses expand their operations.

ARCH Venture Partners, founded in 1986 and headquartered in Illinois, USA, is a venture capital firm that has completed 298 investments to date. The firm primarily invests in biotechnology, health diagnostics, life sciences, and biopharmaceuticals.

F-Prime Capital Partners is a global venture capital firm headquartered in Massachusetts. Founded in 1946, the company primarily invests in healthcare and medical technology. As one of the world’s largest asset managers, it oversees more than $2 trillion in assets under management.

Biomatics Capital Partners, established in 2016, is a venture capital firm headquartered in Seattle. The firm manages a $200 million fund and focuses on early-stage investments in startups within the genomics and digital health sectors, having completed 17 investments to date.

(Compiled by Liu Yujing)